Drug firm Lupin said Monday it has launched the generic Atovaquone oral suspension, which is used for the prevention and treatment of pneumonia, in the US market.
The company has launched its Atovaquone oral suspension USP, 750 mg/5 ml, having received an approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a filing to BSE.
The company's product is the generic version of Glaxosmithkline LLC's Mepron oral suspension in the same strength, it added.
As per IQVIA MAT September 2018 data, Atovaquone oral suspension USP, 750 mg/5 ml had annual sales of around USD 119 million in the US, Lupin said.
The product is indicated for the prevention of pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim/sulfamethoxazole.
It is also for the treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim/sulfamethoxazole, it added.
Shares of Lupin Ltd Monday closed at Rs 860.50 on BSE, up 0.74 per cent from the previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app